Although PARP inhibitors were only approved in HER2-negative advanced breast cancer with germline BRCA1/2 mutation (gBRCAm)33,34, including half of patients displaying ER-positive tumors, clinical trials are now underway to evaluate these compounds in other genetic contexts. Here, ESR1 is linked to breast cancer.